Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Vascular Leak and Hypercytokinemia Associated with Severe Fever with Thrombocytopenia Syndrome Virus Infection in Mice.

Westover JB, Hickerson BT, Van Wettere AJ, Hurst BL, Kurz JP, Dagley A, Wülfroth P, Komeno T, Furuta Y, Steiner T, Gowen BB.

Pathogens. 2019 Sep 21;8(4). pii: E158. doi: 10.3390/pathogens8040158.

2.

Development of a respiratory disease model for enterovirus D68 in 4-week-old mice for evaluation of antiviral therapies.

Evans WJ, Hurst BL, Peterson CJ, Van Wettere AJ, Day CW, Smee DF, Tarbet EB.

Antiviral Res. 2019 Feb;162:61-70. doi: 10.1016/j.antiviral.2018.11.012. Epub 2018 Dec 3.

PMID:
30521834
3.

Evaluation of antiviral therapies in respiratory and neurological disease models of Enterovirus D68 infection in mice.

Hurst BL, Evans WJ, Smee DF, Van Wettere AJ, Tarbet EB.

Virology. 2019 Jan 2;526:146-154. doi: 10.1016/j.virol.2018.10.014. Epub 2018 Oct 31.

PMID:
30390563
4.

Causation of Acute Flaccid Paralysis by Myelitis and Myositis in Enterovirus-D68 Infected Mice Deficient in Interferon αβ/γ Receptor Deficient Mice.

Morrey JD, Wang H, Hurst BL, Zukor K, Siddharthan V, Van Wettere AJ, Sinex DG, Tarbet EB.

Viruses. 2018 Jan 12;10(1). pii: E33. doi: 10.3390/v10010033.

5.

Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.

Morçӧl T, Hurst BL, Tarbet EB.

Vaccine. 2017 Aug 16;35(35 Pt B):4569-4577. doi: 10.1016/j.vaccine.2017.07.016. Epub 2017 Jul 14.

6.

Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties.

Smee DF, Hurst BL, Evans WJ, Clyde N, Wright S, Peterson C, Jung KH, Day CW.

J Virol Methods. 2017 Aug;246:51-57. doi: 10.1016/j.jviromet.2017.03.012. Epub 2017 Mar 27.

7.

Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.

Tao W, Hurst BL, Shakya AK, Uddin MJ, Ingrole RS, Hernandez-Sanabria M, Arya RP, Bimler L, Paust S, Tarbet EB, Gill HS.

Antiviral Res. 2017 May;141:62-72. doi: 10.1016/j.antiviral.2017.01.021. Epub 2017 Feb 2.

8.

Phrenic nerve deficits and neurological immunopathology associated with acute West Nile virus infection in mice and hamsters.

Zukor K, Wang H, Hurst BL, Siddharthan V, Van Wettere A, Pilowsky PM, Morrey JD.

J Neurovirol. 2017 Apr;23(2):186-204. doi: 10.1007/s13365-016-0488-6. Epub 2016 Oct 19.

9.

Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity.

Swanson MD, Boudreaux DM, Salmon L, Chugh J, Winter HC, Meagher JL, André S, Murphy PV, Oscarson S, Roy R, King S, Kaplan MH, Goldstein IJ, Tarbet EB, Hurst BL, Smee DF, de la Fuente C, Hoffmann HH, Xue Y, Rice CM, Schols D, Garcia JV, Stuckey JA, Gabius HJ, Al-Hashimi HM, Markovitz DM.

Cell. 2015 Oct 22;163(3):746-58. doi: 10.1016/j.cell.2015.09.056. Epub 2015 Oct 22.

10.

Influenza Virus H1N1 inhibition by serine protease inhibitor (serpin) antithrombin III.

Smee DF, Hurst BL, Day CW, Geiben-Lynn R.

Int Trends Immun. 2014 Apr 1;2(2):83-86.

11.

A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.

Tarbet EB, Hamilton S, Vollmer AH, Luttick A, Ng WC, Pryor M, Hurst BL, Crawford S, Smee DF, Tucker SP.

J Antimicrob Chemother. 2014 Aug;69(8):2164-74. doi: 10.1093/jac/dku127. Epub 2014 Apr 28.

12.

In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.

Tarbet EB, Vollmer AH, Hurst BL, Barnard DL, Furuta Y, Smee DF.

Arch Virol. 2014 Jun;159(6):1279-91. doi: 10.1007/s00705-013-1922-1. Epub 2013 Dec 6.

PMID:
24311151
13.
14.

Vascular leak ensues a vigorous proinflammatory cytokine response to Tacaribe arenavirus infection in AG129 mice.

Sefing EJ, Wong MH, Larson DP, Hurst BL, Van Wettere AJ, Schneller SW, Gowen BB.

Virol J. 2013 Jul 2;10:221. doi: 10.1186/1743-422X-10-221.

15.

Antivirally active ribavirin analogues--4,5-disubstituted 1,2,3-triazole nucleosides: biological evaluation against certain respiratory viruses and computational modelling.

Krajczyk A, Kulinska K, Kulinski T, Hurst BL, Day CW, Smee DF, Ostrowski T, Januszczyk P, Zeidler J.

Antivir Chem Chemother. 2014 Jan 29;23(4):161-71. doi: 10.3851/IMP2564.

PMID:
23538746
16.

D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis.

Smee DF, Hurst BL, Day CW.

Antivir Chem Chemother. 2012 Aug 21;22(6):263-72. doi: 10.3851/IMP2105.

PMID:
22516927
17.

Effects of TheraMax on influenza virus infections in cell culture and in mice.

Smee DF, Hurst BL, Wong MH.

Antivir Chem Chemother. 2011 Jul 4;21(6):231-7. doi: 10.3851/IMP1744.

PMID:
21730370
18.

Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice.

Smee DF, Hurst BL, Wong MH, Tarbet EB, Babu YS, Klumpp K, Morrey JD.

Antiviral Res. 2010 Oct;88(1):38-44. doi: 10.1016/j.antiviral.2010.07.003. Epub 2010 Jul 13.

19.

Lack of efficacy of aurintricarboxylic acid and ethacrynic acid against vaccinia virus respiratory infections in mice.

Smee DF, Hurst BL, Wong MH.

Antivir Chem Chemother. 2010 Apr 14;20(5):201-5. doi: 10.3851/IMP1480.

PMID:
20413827
20.

Activity of isatine-sulfadimidine derivatives against 2009 pandemic H1N1 influenza virus in cell culture.

Selvam P, Chandramohan M, Hurst BL, Smee DF.

Antivir Chem Chemother. 2010 Jan 5;20(3):143-6. doi: 10.3851/IMP1471.

PMID:
20054101

Supplemental Content

Loading ...
Support Center